hold on there's just too much going on in Congress lmao...
Mandates testing a model to tie certain drug prices to international rates.
Rep. Dan Meuser (R-PA), referred to House committees for review.
Introduced in House, awaits committee review.
This bill, introduced by Representative Dan Meuser (R-PA), requires the Center for Medicare and Medicaid Innovation to test a 'Most Favored Nations Pricing Model' for certain drugs. This model, if implemented, would link drug prices for specific Medicare and Medicaid beneficiaries to prices paid in other developed countries. The bill has been referred to the House Energy and Commerce and Ways and Means committees for consideration, meaning it has taken an initial step in the legislative process but has a long way to go.
Introduced Mar 5, 2026
The bill was introduced in the House of Representatives by Representative Dan Meuser and immediately referred to the House Energy and Commerce Committee and the House Ways and Means Committee. These committees will review the bill, hold hearings, and potentially amend it before deciding whether to send it to the full House for a vote. It must pass both the House and Senate and be signed by the President to become law.
If this bill becomes law, certain drug prices paid by Medicare (Parts B, C, D) and Medicaid beneficiaries, as well as hospitals and physicians, could be tied to the second-lowest prices found in countries like Canada, Germany, or the UK. This means you might see lower costs for some prescriptions. Drug manufacturers could also be incentivized to increase their manufacturing operations in the United States to avoid participating in this pricing model.
Supporters Say
Proponents believe this model will lower drug costs for American patients by using international pricing benchmarks.
Critics Say
Critics might argue it could discourage drug innovation or limit drug availability in the U.S. market.
Supporters of a 'most-favored-nation' approach generally contend that it leverages international market prices to make prescription drugs more affordable for Americans. They would point to the potential for significant savings for government programs and patients. Those who oppose such models often raise concerns that linking U.S. drug prices to lower foreign prices could reduce pharmaceutical companies' revenue, thereby stifling research and development for new drugs or leading companies to prioritize other markets.